In an interview two years ago, Orexigen Chief Executive Mike Narachi understood that data from the largest clinical trial of his company’s weight loss drug Contrave were to be kept secret except for ...
Shares in Orexigen Therapeutics, the maker of a weight-loss drug called Contrave, have dropped 24% to $5 since Tuesday, when news came out that data that the drug maker had originally presented as ...
U.S. health regulators rejected Orexigen Therapeutics Inc's weight-loss drug and requested a clinical trial to resolve heart safety concerns, dealing a stunning blow to what stood to be the first new ...
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical ...
WASHINGTON (AP) — Orexigen Therapeutics Inc. said Tuesday that U.S. health officials declined to approve the experimental weight loss pill Contrave and want the company to conduct an additional study ...
SAN DIEGO — Obesity may be on the rise, but the market for fat-loss pills? Flat. Exhibit A: the recent maneuverings of Orexigen Therapeutics, which sells a moderately effective anti-obesity drug ...
If there was one pill in the latest crop of experimental weight-loss medicines that stood a chance of getting the nod from the Food and Drug Administration, it looked like Orexigen's Contrave. But FDA ...
Welcome to the Second Quarter 2014 Orexigen Therapeutics Incorporated Earnings Conference Call. My name is John and I’ll be your operator for today’s call. At this time, all participants are in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback